Featured Content
Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining ...
Six-Month Trastuzumab Sufficient for HER2-Positive Early Stage Breast Cancer
Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.
Can Oncolytic Viruses Improve Immunotherapies?
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Clonally Transmissible Cancers in Nature
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that ...
New Methodology May Advance Precision Medicine
A new technology is being developed by Caris Life Sciences to help improve the understanding of aberrant modulations that drive cancer.More Features>>>
Video Series
-
The Phase 3 PlanB Trial
-
Continue to Work?
-
Drug Resistance to CDK4/6 Inhibitors
-
Comparing Ribociclib and Palbociclib
-
Ribociclib, Abemaciclib, and Palbociclib
-
The Potential of CDK4/6 Inhibitors
-
How Cyclin D Plays A Role
-
Role of Cell Cycle in Progression
-
2016 SABCS: Clinical Insights
-
2016 SABCS: Clinical Insights
-
HER2-positive Metastatic and TNBC
-
Frontline Treatments
-
Treatment-related Neuropathy
-
ER-positive, HER2-negative
-
Emerging Medicines
-
Triple-negative Breast Cancer
-
Insights from the Lab and Clinic
-
Trastuzumab Resistance
-
Biologic Role of HER2
-
Strategies in Management
-
Lapatinib-based Regimen
-
Overcoming Trastuzumab Resistance
-
New Anti-HER2 Agents
-
HER2-targeted Therapies
-
Lapatinib and the Neoadjuvant Tx
-
Predicting Response/Resistance
-
AC-THP vs. TCHP Treatment
Breast Cancer News
Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26
SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer
First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer
Breast Cancer Resources
More Breast Cancer Information
Coffee and Cancer
Several meta-analyses suggest that coffee consumption may decrease the risk of many types of cancers, but for some cancers, the data remain mixed or indicate an increased risk.
Acupuncture and Cancer
Though the mechanisms of action of acupuncture are not well-understood and continue to be an area of research, hypotheses include changes in neurohormones and immunomodulation through cytokines.
Amygdalin and Cancer
While some in vitro data suggests anticancer activity, animal and in-human studies fail to show efficacy and the risk of cyanide toxicity make amygdalin not recommended for use.
Cannabis and Cancer
Cannabis and its synthetic cannabinoids have been studied for medicinal properties across multiple disease states.
Essential Oils and Cancer
In-human studies have evaluated the use of EOs in a supportive role, and though EOs appear to have some efficacy in this setting, larger studies are needed to confirm their effects.
The Treatment Landscape of Breast Cancer
The treatment landscape in breast cancer has evolved dramatically within the past several decades.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Coffee and Cancer
- Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic
- Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC
- Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia
- Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma
- In Melanoma, Older Adults Could Benefit More From Treatment with PD-1 Inhibitors
- JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas
- Coffee and Cancer
- Pembrolizumab FDA-Approved for the Treatment of Advanced Cervical Cancer
- Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC